This segment also handles the formulation, development and manufacturing for parenteral dose forms, including vials and prefilled syringes.
Activist Commentary: Elliott is a very successful and astute activist investor, particularly in the technology sector.
While as an activist Elliott will do whatever it feels is necessary to enhance shareholder value, in the past the firm has made significant use of the strategy of offering to acquire its portfolio companies as the best catalyst to enhance shareholder value.
Like Catalent, Syneos is an outsourced pharma solutions company: It outsources R&D for pharmaceutical companies, whereas Catalent outsources manufacturing.
If this does turn from a strategic review to an operational review, there is no guarantee that he keeps his job.
Persons:
Catalent, there's, Elliott, Steven Barg, Frank D'Amelio, Stephanie Okey, Michelle Ryan, Johnson, Barg, Ryan, John Greisch, There's, Danaher, Alessandro Maselli, Ken Squire
Organizations:
Oral Technologies, Clinical, Pfizer, Rom Holdings, Bloomberg, Merck, Citrix Systems, Nielsen Holdings, Square, Veritas Capital, Syneos Health, 13D
Locations:
COOs, North America